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When facing an emerging virus outbreak such as 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), a quick reaction time is key to control 
the spread. It takes time to develop antivirals and 
vaccines, and implement vaccination campaigns. 
Therefore, preventive measures such as rapid isola-
tion of cases and identification and early quarantine 
of cases’ close contacts—as well as masks, physical 
distancing, hand hygiene, surface disinfection and air 
control—are crucial to reduce the risk of transmission. 
In this context, disinfectants and antiseptics with 
proven efficacy against the outbreak virus should be 
used. However, biocidal formulations are quite com-
plex and may include auxiliary substances such as sur-
factants or emollients in addition to active substances. 
In order to evaluate disinfectants’ efficacy objectively, 
meaningful efficacy data are needed. Therefore, the 
European Committee for Standardisation technical 
committee 216 ‘Chemical disinfectants and antisep-
tics’ Working Group 1 (medical area) has developed 
standards for efficacy testing. The European tiered 
approach grades the virucidal efficacy in three levels, 
with corresponding marker test viruses. In the case of 
SARS-CoV-2, disinfectants with proven activity against 
vaccinia virus, the marker virus for the European claim 
‘active against enveloped viruses’, should be used 
to ensure effective hygiene procedures to control the 
pandemic.
Background
When facing an emerging infectious disease outbreak, 
a quick reaction time is crucial to control the spread. 
However, it takes time to develop and produce thera-
peutics and/or vaccines [1]. The challenge becomes 
even greater with a fast-spreading disease such as cor-
onavirus disease (COVID-19) [2]. Like viruses that cause 
severe acute respiratory syndrome (SARS), Ebola virus 
disease, Middle East respiratory syndrome (MERS) 
and Nipah virus infection, SARS coronavirus 2 (SARS-
CoV-2)—the causing agent of COVID-19—is an example 
of a virus that has emerged at the human-animal inter-
face within the last two decades [2-6]. Additionally, air 
travel has facilitated an increasingly interconnected 
world with more frequent cross-border movements of 
people and trade goods, enabling the rapid spread of 
infectious diseases globally [7].
Measures are needed to control COVID-19, whether 
these are non-pharmaceutical, a pharmaceutical pro-
phylactic or a pharmaceutical treatment [8,9]. Though 
COVID-19 pandemic activity decreased in Europe in the 
early summer months of 2020, a second wave began in 
autumn and it is possible that additional waves could 
occur this winter [10]. Non-pharmaceutical measures 
(NPM)—including rapid isolation of positively tested 
cases and identification and early quarantine of cases’ 
close contacts, as well as barriers such as masks, 
physical distancing [11], hand hygiene, surface disin-
fection and air control in concerned hospital settings—
remain crucial to reduce the risk of person-to-person 
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Table 1
Standard test methods to substantiate activity claims for medical products for hand, surface and instrument disinfection, 
according to EN 14885
Type of activity Test virus
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2/2 NA NA NI EN 16777 Approvedc






















(MNV, strain S99) 
 
Non-enveloped
2/1 EN 14476 EN 14476 NI EN 14476 EN 14476 NI
Adenovirus 
 





















Poliovirus type I 
 













(MNV, strain S99) 
 
Non-enveloped
2/1 EN 14476 EN 14476 NI EN 14476 EN 14476
EN 14476 
 



























approvedb NI EN 16777
Not yet 
approvedb
EN 17111 [30] 
 




MNV: murine norovirus; MVA: modified vaccinia virus Ankara; MVM: minute virus of mice; NA: not applicable; NI: no intention to develop a test; PV1: poliovirus 
type 1.
a EN 14476 is not applicable for surgical handrub and handwash products because surgical products are designed to be effective against resident microbiota and 
viruses are part of the transient microbiota.
b No work item yet approved, but relevant standards may become available in the future.
c Work item approved.
d Must be tested in the corresponding suspension test; poliovirus cannot be used for surfaces, because of drying problems.
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transmission of SARS-CoV-2 by asymptomatic, pre-
symptomatic or symptomatic infected persons in 
healthcare and non-healthcare (e.g. community) 
settings.
The use of antiseptics and disinfectants has long been 
a widely accepted part of infection prevention and con-
trol to support healthcare professionals, patients and 
people at higher risk of serious illness with rapid and 
efficacious measures. In general, biocidal disinfectant 
or antiseptic formulations are complex and may include 
auxiliary substances such as surfactants or emollients 
in addition to active substances, which can influence 
the effect of the disinfectant. Therefore, recommend-
ing to use a product that contains a certain biocidal 
active substance is not adequate to identify suitable 
products.
In general, it is important to have a standardised test 
protocol for comparing the efficacy of disinfectant and 
antiseptic products [12]. In order to select antiseptics 
and disinfectants with proven efficacy, the European 
Committee for Standardisation (CEN, Comité Européen 
de Normalisation in French) established the techni-
cal committee (TC) 216 in 1990 for chemical disinfect-
ants and antiseptics. The scope of this TC is to set up 
guidance for the standardisation of the terminology, 
requirements, test methods (including potential effi-
cacy under in-use conditions), recommendations for 
use and labelling of chemical disinfectants and anti-
septics. This committee consists of delegates from dif-
ferent European countries, with representatives from 
governments, competent authorities (i.e. public health 
institutes, regulatory authorities), official institutes, 
universities, test laboratories and manufacturers of 
antiseptics and disinfectants.
European standards for testing antiseptics and disin-
fectants are based on a tiered approach, using relevant 
surrogate test organisms. This helps to facilitate effi-
cacy tests and to develop adequate practical recom-
mendations regarding the disinfectants that can be 
used immediately in an ongoing outbreak, which will 
add confidence to the bundle of measures necessary to 
prevent spread of infectious diseases.
Test principle of European standards: 
surrogate test viruses and tiered test 
approach in EN 14476
Information on the efficacy of disinfectants and anti-
septics against emerging enveloped viruses such as 
Ebola virus (EBOV) or SARS-CoV-2 is limited because 
of the high biosafety level (BSL) of these viruses or 
because they are not available in laboratories, par-
ticularly at the beginning of an outbreak. To avoid this 
problem, vaccinia virus (modified vaccinia virus Ankara 
(MVA) or vaccinia virus strain Elstree, respectively) was 
introduced as a surrogate virus for the European claim 
‘active against enveloped viruses’ in 2015, after in vitro 
studies comparing MVA with EBOV, SARS-CoV-1 and 
MERS-coronavirus (CoV) using povidone-iodine (PVP-I) 
showed that vaccinia virus was the most resilient virus 
[13,14]. This is in line with a publication that demon-
strated in its investigation of enveloped viruses—such 
as Zika virus, EBOV and coronaviruses—that vac-
cinia is a suitable and safe surrogate when looking 
at the virucidal efficacy of alcoholic formulations for 
hand disinfectants [15]. Meanwhile, the efficacy of 
these disinfectants (PVP-I and alcoholic World Health 
Organization formulations) has also been proven 
against SARS-CoV-2 [16,17].
The European approach with surrogate organisms has 
been effective for more than 60 years against bacteria 
and for about 40 years against viruses, e.g. in German 
national standards. The choice of surrogate viruses 
is of great importance when establishing a standard-
ised test. The requirements for standardised surrogate 
viruses are: high resistance to disinfectants and dry-
ing, combined with simple virus propagation in cell cul-
ture, availability in virus collections and a low BSL (BSL 
1 and 2). For example, 30 years ago, European virucidal 
activity tests focused only on the most resistant virus: 
hepatitis A, a picornavirus that it is difficult to handle 
in a routine testing laboratory. The poliovirus 1 Sabin 
vaccine strain Lsc-2ab, another picornavirus, can eas-
ily be handled in cell culture for virus propagation and 
therefore became the first surrogate virus for the claim 
‘virucidal activity’.
Presently, the tiered approach on the virucidal stand-
ard EN 14476 [18] consists of two parts: three differ-
ent activity levels and two kinds of test methods, as 
shown in Table 1.
The three European virucidal activity levels take into 
account that enveloped viruses contain lipids and have 
lipophilic properties (Box). These viruses are sensitive 
to disinfectants that contain active substances that 
disrupt their lipid bilayer envelope. In contrast, non-
enveloped viruses are usually hydrophilic and less sus-
ceptible to disinfectants. Thus, viruses can be grouped 
according to these properties (Table 2).
Test methods to prove efficacy of a 
disinfectant
The CEN/TC 216 requires a stepwise procedure for effi-
cacy testing of disinfectants, i.e. first a test in suspen-
sion (EN phase 2, step 1), followed by a test simulating 
practical conditions in the laboratory (EN phase 2, step 
2). This tiered approach, including organic soiling, is 
described in the framework standard EN 14885 [19]. 
The quantitative suspension test EN 14476 is a phase 
2, step 1 test [18] and is the first tier to evaluate the 
performance of the disinfectant in terms of concentra-
tion and contact time ratio. The EN 14476 demands a 4 
log reduction (deactivating 99.99%) of the respective 
test viruses as the minimum measure of efficacy. In 
addition, activity tests have to be performed in com-
pliance with adequate quality assurance systems and 
according to valid test procedures, as described in the 
relevant European standard(s) [19]. In recent years, 
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Table 2
Activity spectrum of the surrogate viruses for virucidal efficacy testing
Activity claim   Test virus Activity spectrum (examplesa)








Viruses causing blood-borne infections 
 
Hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) 
 
Viruses causing respiratory infections 
 
Human coronaviruses (e.g. SARS-CoV-2 and MERS-CoV), influenza virus A (e.g. subtype 
H1N1, H3N2) and B, metapneumovirus, respiratory syncytial virus (RSV) 
 
Viruses causing other viral infections 
 
Herpesviridae (cytomegalievirus (CVMV), herpes-simplex-virus types 1 and 2 (HSV-1, 
HSV-2), Epstein-Barr virus (EBV), varizella zoster virus (VZV)) 
 
Paramyxoviruses (Nipah virus, measles virus, mumps virus, rubella virus) 
 
Viruses causing travel-associated or vector-borne infections 
 
Bunyavirus (sandfly fever virus), dengue virus (DENV), Ebola virus (EBOV), tick-borne 
encephalitis virus (TBEV), Hantaan virus, Crimean-Congo hemorrhagic fever virus, 
Lassa virus, Marburg virus, rabies virus, West Nile virus (WNV), Yellow fever virus 
(YFV), Zika virus
Limited spectrum of virucidal 
activity: 
 




(adenovirus type 5, 






(MNV, strain S99) 
 
Non-enveloped
Viruses mentioned above 
 
Viruses causing viral gastrointestinal infections 
 
Adenovirus serotypes 40 and 41, norovirus, rotavirus 
 
Viruses causing respiratory infections 
 
Adenovirus serotype 7 
 
Viruses causing keratoconjunctivitis 
 
Adenovirus serotypes 8, 19 and 37
Virucidal activity: 
 
non-enveloped viruses and 
enveloped viruses









(adenovirus type 5, 






(MNV, strain S99) 
 
Non-enveloped
Viruses mentioned above 
 
Viruses causing gastrointestinal infections 
 
Adenovirus serotypes 40 and 41, norovirus, rotavirus 
 
Viruses causing respiratory infections 
 
Adenovirus serotype 7 
 
Viruses causing keratoconjunctivitis 
 
Adenovirus serotypes 8, 19 and 37 
 
Viruses causing other virus infections 
 
Enteroviruses (Coxsackie virus, echovirus, polioviruses, rhinoviruses, enterovirus 71, 
Enterovirus 68 (EV-D68)) 
 
Parechoviruses (echovirus 22 and 23)
Chemothermal 
disinfection ≥ 40 °C
Murine parvorvirus 
 
(minute virus of 




Textile disinfection or instrument disinfection
MVA: modified vaccinia virus Ankara.
a This list is not exhaustive.
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tests simulating practical conditions have been devel-
oped for surface, instrument and hand disinfectants 
that take into account the application of a specific dis-
infectant under evaluation.
Phase 2, step 2 tests reflecting close to real-life 
conditions
Surface disinfection
Viruses may persist on surfaces for several days or 
even months [20] and can be transferred directly from 
contaminated surfaces to susceptible individuals 
[21]. Therefore, the disinfection of surfaces frequently 
touched by patients and staff such as door handles, 
faucets and railings plays an important role in the pre-
vention and control of viral outbreaks in healthcare 
settings. Disinfectants must be tested for their effi-
cacy under standardised, close to real-life conditions 
to ensure that they are able to inactivate viruses. This 
approach has long been standardised according to 
European principles for testing the bactericidal activ-
ity of chemical disinfectants [22,23]. Bactericidal disin-
fectants are tested stepwise according to European test 
principles, starting with a suspension test (EN phase 
2, step 1) and then a quantitative non-porous carrier 
test simulating practical conditions (EN phase 2, step 
2) [18]. It is also possible for the activity of virucidal 
products intended for surface disinfection to be tested 
under practical conditions (phase 2, step 2) according 
to the EN 16777 standard [24,25].
Handrub disinfection
In order to further improve our knowledge of the time/
concentration relationships of handrubs, taking into 
consideration practical conditions for use in clinical 
surroundings, more practical testing (phase 2, step 2 
tests) are necessary, such as the EN 1500 for evaluating 
the bactericidal efficacies of hygienic handrubs [26]. 
In such tests, the bactericidal efficacy of products is 
compared with that of a reference procedure on hands 
of volunteers artificially contaminated with Escherichia 
coli  K12. Since most emerging viruses are enveloped 
viruses, a relevant surrogate for products with activity 
against enveloped viruses should be sought. More than 
30 years ago, tests with vaccinia virus were performed 
on the fingertips of volunteers [27]; however, today 
this can no longer be justified ethically due to safety 
concerns. Thus, there is currently no approved surro-
gate enveloped virus available for testing hand hygiene 
products that is harmless and can be used in studies 
with volunteers. Until a suitable assay with an appro-
priate surrogate can be proposed, only data of the EN 
14476 suspension test (phase 2, step 1) is available. 
However, there is a preliminary phase 2, step 2 stand-
ard prEN 17430 [28] that employs the murine norovi-
rus strain S99, a non-enveloped and non-pathogenic 
RNA virus to simulate practical conditions for virucidal 
hygienic handrub products; this is harmonised with the 
EN 1500 standard. Being more resistant to chemicals 
than enveloped viruses, the murine norovirus can be 
considered a suitable surrogate to support the claims 
‘limited spectrum virucidal activity’ and ‘virucidal 
activity’ (if all criteria have been met in a phase 2, step 
1 test) based on the tiered concept of CEN/TC 216 [29].
Conclusions
Disinfectants and antiseptics are part of the bundle of 
measures necessary to achieve infection prevention 
and control in healthcare settings and the community. 
The European tiered approach of grading the viru-
cidal efficacy as ‘virucidal activity against enveloped 
viruses’, ‘limited spectrum of virucidal activity’ and 
‘virucidal activity’ helps to select the most appropri-
ate claim for emerging or re-emerging virus outbreaks, 
with a proven concentration and contact time. This 
leads to the correct choice of test method to determine 
the appropriate use, concentration and contact time of 
antiseptics and disinfectants.
The standards outlined in Table 1 are subject to mutual 
recognition in the European Union and replace previous 
national standards. Furthermore, the standardised test 
protocol based on the use of surrogate viruses and two 
methodical steps also helps to compare formulations 
in an objective way, thus providing proven efficacy to 
the end user.
Box  
European virucidal activity levels
• Virucidal activity against enveloped viruses: Activity against enveloped viruses (e.g. influenza (including avian influenza 
A (H7N9)), herpes viruses, HIV, HBV, HCV, Zika virus, Ebola virus, coronaviruses (including SARS-CoV-2 and MERS-CoV) and 
flaviviruses). This claim is for hand disinfection, surface disinfection and pre-cleaning products for instruments, which are combined 
cleaner/disinfectants.
• Limited spectrum virucidal activity: Activity against non-enveloped noroviruses, rotaviruses, adenoviruses and enveloped viruses. 
This claim is for hand disinfection and surface disinfection.
• Virucidal activity: Activity against viruses, including non-enveloped (e.g. polioviruses and enteroviruses, such as enterovirus 71 
and enterovirus D68) and enveloped viruses. This claim is for hand disinfection, surface disinfection, instrument disinfection and 
textile disinfection.
HBV: hepatitis B virus; HCV: hepatitis C virus; MERS-CoV: Middle East respiratory syndrome coronavirus; SARS-CoV-2: severe acute 
respiratory syndrome coronavirus 2.
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